TEVA PHARMACEUTICAL INDUSTRIES LTD·4

May 7, 4:01 PM ET

Daniell Richard 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed May 7, 2026

Research Summary

AI-generated summary of this filing

Updated

Teva (TEVA) EVP Daniell Richard Sells 30,000 Shares

What Happened Daniell Richard, EVP, Europe Commercial at Teva Pharmaceutical Industries Ltd (TEVA), disposed of 30,000 shares on 2026-05-05. The Form 4 reports the sale at $35.40 per share for a total transaction value of $1,062,000. The filing lists the transaction as an open market or private sale (code S).

Key Details

  • Transaction date and price: 2026-05-05 — 30,000 shares at $35.40 each.
  • Total value: $1,062,000.
  • Shares owned after transaction: Not disclosed in the filing.
  • Footnote: F1 — Ordinary shares may be represented by American Depositary Shares (each ADS currently represents one Ordinary Share).
  • Filing timeliness: Reported on Form 4 filed 2026-05-07; appears filed within the normal two‑business‑day window (timely).

Context This was a straight sale (disposition), not an option exercise or award. Sales by insiders can be routine (e.g., diversification, personal liquidity, or tax reasons) and do not by themselves indicate a change in the insider’s view of the company. Retail investors often watch for patterns of repeated insider buying or selling rather than a single sale.

Insider Transaction Report

Form 4
Period: 2026-05-05
Daniell Richard
EVP, Europe Commercial
Transactions
  • Sale

    Ordinary Shares

    [F1]
    2026-05-05$35.40/sh30,000$1,062,00055,755 total
Footnotes (1)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Signature
/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell|2026-05-07

Documents

1 file
  • 4
    ownership.xmlPrimary

    4